JNJ Stock was trading at $164.91 as of 12:24 PM EDT.
The Teligen system from Johnson & Johnson ( NYSE:JNJ ) has been given 510(k) clearance by the FDA for use in specific spine surgical procedures. Using digital technologies for imaging and access, Teligen, created by J&J’s Orthopaedics division DePuy Synthes, offers minimally invasive surgical transforaminal lumbar interbody fusion (MIS-TLIF) surgeries.
According to a press release from the company on Thursday, the system is anticipated to be made accessible in the United States later this year.
“We’re delivering a better field of view to help improve patient care and increase efficiency with our ground-breaking TELIGEN Technology Platform. This development from the DePuy Synthes team and how the VueLIF-T will alter MIS spinal operations make me tremendously proud “said Russell Powers, president of DePuy’s global spine business.
Tuesday’s premarket trade saw shares of Johnson & Johnson ( NYSE:JNJ ) rise 2.3% toward a two-month high after the pharmaceutical and consumer goods firm reported third-quarter profit and sales that exceeded expectations across all of its business groups. From $3.67 billion, or $1.37 per share, at the same time last year, net income increased to $4.46 billion, or $1.68 per share. Adjusted earnings per share fell to $2.55 from $2.60 when nonrecurring events were excluded, although this was still higher than the FactSet consensus estimate of $2.48.
JNJ Stock: 3 Reasons to Love It
Why is JNJ Stock with such low volatility? Because it’s the closest thing to a ...
Click here to read the full article on PressReach.com .Subscribe to the PressReach RSS feeds:
- Featured News RSS feed
- Investing News RSS feed
- Daily Press Releases RSS feed
- Trading Tips RSS feed
- Investing Videos RSS feed
Follow PressReach on Twitter
Follow PressReach on TikTok
Follow PressReach on Instagram
Subscribe to us on Youtube